FDA Approved: XYZAL — Supplemental Application (Chattem, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for XYZAL (levocetirizine dihydrochloride) from Chattem, Inc., resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Idiopathic Urticaria

Drugs mentioned

• XYZAL (LEVOCETIRIZINE DIHYDROCHLORIDE)

Snippet

SUPPL AP for XYZAL (LEVOCETIRIZINE DIHYDROCHLORIDE)